Evidence map›Paper›PMID 41286156›Full record

ArticleFamilial cancer2025

Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis.

Aleksander M Bogdanski, Derk C F Klatte, Sobia I Laghari, Alexandra M J Langers, Ananya Das, Barbara A J Bastiaansen, Bert A Bonsing, Evelien Dekker, Jeanin E Van Hooft, Jewel N Samadder and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Familial cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Aleksander M BogdanskiDepartment of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Derk C F KlatteDepartment of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Sobia I LaghariDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Alexandra M J LangersDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Ananya DasArizona Centers for Digestive Health, Gilbert, AZ, USA.
Barbara A J BastiaansenDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Bert A BonsingDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Evelien DekkerDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Jeanin E Van HooftDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Jewel N SamadderDepartment of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.
Lodewijk A A BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Lydia G van der GeestDepartment of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
Lisa BoardmanDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Maartje NielsenDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Mariëtte C A van KouwenDepartment Gastroenterology and Hepatology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.
Tanya M BisselingDepartment Gastroenterology and Hepatology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.
Michael B WallaceDepartment of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Douglas Riegert-JohnsonDepartment of Clinical Genomics and Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Monique E van LeerdamDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. m.v.leerdam@nki.nl.ORCID 0000-0002-5719-3208
Dutch Pancreatic Cancer Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PDAC) surveillance programs are recommended for individuals with a PDAC lifetime-risk ≥ 5% to improve outcomes. While familial adenomatous polyposis (FAP) is linked to increased PDAC risk, robust data to guide surveillance recommendations is lacking. This study evaluates PDAC risk in a large FAP-cohort.Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic APC variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic APC variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. The US-cohort (n = 357) and NL-cohort (n = 1000) had a median age at the end of follow-up of 46 years (IQR, 32.0-60.0) and 60 years (IQR, 47.5-72.5), respectively. The cumulative risk of PDAC by age 70 was 1.3% (95% CI, 0.2-8.4) in the US cohort and 0.6% (95% CI 0.2-1.7) in the NL cohort. When combining both FAP-cohorts, the cumulative risk of PDAC by age 70 was 0.7% (95% CI, 0.3-1.8). For comparison, the cumulative incidence of PDAC in the general population at age 70 was 0.3% (95% CI 0.3-0.3), corresponding to a relative risk of 2.2 (95% CI, 0.9-5.7). Our findings indicate that PDAC risk in FAP patients is not statistically significantly higher than in the general population. As the cumulative incidence remains below the 5% threshold, PDAC surveillance is not recommended.

Indexed as

Adenomatous Polyposis ColiCarcinoma, Pancreatic DuctalEarly Detection of CancerPancreatic NeoplasmsAdenomatous Polyposis Coli ProteinAdolescentAdultAgedFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedNetherlandsPractice Guidelines as TopicAdenomatous Polyposis Coli ProteinAPC protein, humanFamilial adenomatous polyposisPancreatic cancerSurveillance

Identifiers

PMID41286156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.